NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-NS-22-069 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-146 from the NIH Guide for Grants and Contracts. This FOA solicits Research Education Grant (R25) applications to develop and implement a short course focused on (1) steps required for successful medical device development, translation, and commercialization (2) common technical and strategic challenges, and (3) best-practices and resources for each stage in the process. Applicants may choose to include an extended mentorship plan if they see fit. The short course should address a broad audience, including senior post-doctoral fellows, independent academic researchers, clinician scientists, and small business entrepreneurs interested in developing, translating, and/or commercializing medical devices to diagnose or treat a nervous system disorder.
Notice NOT-CA-22-084 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-109 from the NIH Guide for Grants and Contracts
Notice NOT-AI-22-042 from the NIH Guide for Grants and Contracts
Notice NOT-DK-22-020 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AR-23-002 from the NIH Guide for Grants and Contracts. NIAMS Rheumatic Diseases Research Resource-based Centers (P30 - Clinical Trial Not Allowed)
Notice NOT-AI-22-048 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-22-021 from the NIH Guide for Grants and Contracts. The NIH Director's Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations, are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.
Notice NOT-RM-22-013 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-040 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.
Notice NOT-RM-22-012 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-083 from the NIH Guide for Grants and Contracts
Notice NOT-DE-22-005 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-22-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of Technology-enhanced training products for the health and safety training of: hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biological hazard response, infectious disease response, and medical waste cleanup; emergency responders in disasters; and worker resiliency training. Technology-enhanced training products as defined by the Worker Training Program (WTP) include, but are not limited to, online training, mobile device training, virtual reality, and serious gaming. These advanced technologies complement all phases of training from development to evaluation and can enhance, supplement, improve, and provide health and safety training for hazardous materials workers. These products must complement the goals and objectives of WTP. The major objective of the NIEHS WTP is to prevent work related harm by training workers in how best to protect themselves and their communities from exposure to hazardous materials. The financial support for this initiative comes directly from NIEHS Worker Education and Training Branch SBIR funds.
Funding Opportunity RFA-DA-23-012 from the NIH Guide for Grants and Contracts. The blood brain barrier (BBB) is a target of both the HIV virus and substances of abuse. It is a site of entry for HIV infected monocytes and macrophages that can traverse the BBB either paracellularly or transcellularly. HIV viral proteins can also attack astrocytes and tight junctions of BBB directly and compromise its integrity, resulting in the crossing of the virus, as well as abused substances, into the brain. Meanwhile, many substances of abuse cause BBB dysfunction. Because BBB integrity regulates both substances and virus levels in the brain, it is critical to establish the mechanisms by which HIV infection, in combination with substances of abuse, affect BBB function and integrity and their consequences. The purpose of this initiative is to support innovative research that elucidates the roles of HIV and addictive substances in the pathology of BBB. This FOA encourages studies to expand the current understanding of the basic molecular mechanisms underlying virus mobilization across BBB, and pathology of BBB in HIV infection and substance use disorders (SUD). In addition, studies are encouraged to develop and test novel BBB models to assess the delivery of pharmacological and immunotherapies to treat HIV infection and SUD, and to suppress HIV replication in CNS.
Notice NOT-OD-22-113 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-23-031 from the NIH Guide for Grants and Contracts. The goal of the Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) program is to provide support for early-career physician-scientists trained in medical or surgical specialties and early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. In support of the program's goal, this GEMSSTAR Funding Opportunity Announcement (FOA) provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects.
Funding Opportunity RFA-MH-22-230 from the NIH Guide for Grants and Contracts. This initiative is to support Basic and clinical studies to identify mechanisms by which gut microbiota/ gut immune system altered by HIV impact mental health outcomes in people living with HIV. The goal of this initiative is to investigate mechanisms by which the gut microbiome and gut immune system modulates the brain functions, circuits, neurotransmitters, signaling pathways and synaptic plasticity in the context of HIV and Anti-retroviral therapy.
Notice NOT-NS-22-049 from the NIH Guide for Grants and Contracts